Dendritic cell and B cell response to Campylobacter predisposing to Guillain-Barré syndrome.
- Conditions
- acute inflammatory demyelinating polyneuropathyno lay-term10034606
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
Healthy controls (partners, non-related family members or friends of the (ex)-GBS patients):
- Age 18 years or older
- Written informed consent given by the subject.
Ex-GBS patients:
- Fulfilling the diagnostic criteria for GBS (Asbury, 1990)
- Culture-proven and/or positive serology for C. jejuni (at time of diagnosis).
- Current age: 18 years or older
- Diagnosis of GBS was made after 1987 and at least one year before inclusion in the study.
- Patients were treated at the ward of the department of Neurology, Erasmus MC, or at the Sophia Children*s Hospital.
- Written informed consent was given by the subject.
Both groups:
- Additional diseases or disorders at the time of diagnosis or at time of blood sampling that may influence the endpoints:
*autoimmune diseases (like multiple sclerosis, psoriasis, Crohn*s disease, ulcerative colitis, hepatitis, rheumatoid arthritis, SLE and other systemic diseases)
*acute and chronic infectious diseases (like infectious mononucleosis, HIV/AIDS)
*malignancies (not in remission);- Medicines at time of blood sampling that may affect endpoints (i.e. inflammatory processes):
*NSAIDs, corticosteroids, cyclosporine
*Cytostatic compounds
*Cytokines (analogues) and biologicals
*Intravenous immunoglobulins.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The DC response to LOS as determined by: 1) B-cell proliferative capacity; 2)<br /><br>production of cytokines, including interferon (IFN)-β, interleukin (IL)-6,<br /><br>IL-10, IL-12 and tumor necrosis factor (TNF)-a; and 3) expression of<br /><br>differentiation markers, including CD40, CD80, CD86 and HLA-DR. </p><br>
- Secondary Outcome Measures
Name Time Method <p>Gene expression profile of DC stimulated with C. jejuni LOS of (ex-)GBS<br /><br>patients and healthy controls.</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.